Catalog No.
DHG54901
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG2-kappa
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
MAdCAM-1, hMAdCAM-1, MADCAM1, Mucosal addressin cell adhesion molecule 1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q13477
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
PF-00547659, PF-547659, SHP647, CAS: 2098790-40-8
Clone ID
Ontamalimab
Note
For research use only. Not suitable for clinical or therapeutic use.
Blood pressure lowering effects of a new long-acting inhibitor of phosphodiesterase 5 in patients with mild to moderate hypertension., PMID:19398651
Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases., PMID:25110260
Physiologically relevant binding affinity quantification of monoclonal antibody PF-00547659 to mucosal addressin cell adhesion molecule for in vitro in vivo correlation., PMID:27760281
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial., PMID:28527704
Towards therapeutic choices in ulcerative colitis., PMID:28527707
IBD: Phase II trial success for anti-MADCAM1 antibody., PMID:28611481
Normal intrathecal leukocyte cell number and composition do not decrease the incidence of post-lumbar puncture headache., PMID:28778448
Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA Study., PMID:28961770
Anti-MAdCAM Antibody Increases ß7+ T Cells and CCR9 Gene Expression in the Peripheral Blood of Patients With Crohn's Disease., PMID:28961803
Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study., PMID:28982740
Targeting Endothelial Ligands: ICAM-1/alicaforsen, MAdCAM-1., PMID:29757363
Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease., PMID:29767705
PF-00547659 for the treatment of Crohn's disease and ulcerative colitis., PMID:29985060
Rational and clinical development of the anti-MAdCAM monoclonal antibody for the treatment of IBD., PMID:30696342
Molecular Profiling of Ulcerative Colitis Subjects from the TURANDOT Trial Reveals Novel Pharmacodynamic/Efficacy Biomarkers., PMID:30901380
Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances., PMID:31127023
Anti-trafficking agents in the treatment of inflammatory bowel disease., PMID:31567498
Anti-MADCAM therapy for ulcerative colitis., PMID:31709847
Population Pharmacokinetics and Pharmacodynamics of Ontamalimab (SHP647), a Fully Human Monoclonal Antibody Against Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1), in Patients With Ulcerative Colitis or Crohn's Disease., PMID:32119128
Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II., PMID:33599720
Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study., PMID:34427633
Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): insights into promising agents., PMID:34449288
Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives., PMID:34466013
Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease., PMID:35165437
Review article: emerging drug therapies in inflammatory bowel disease., PMID:35166398
The Underappreciated Role of Secretory IgA in IBD., PMID:36943800
Differential Effects of Ontamalimab Versus Vedolizumab on Immune Cell Trafficking in Intestinal Inflammation and Inflammatory Bowel Disease., PMID:37208197
Promising phase II biologics for future Crohn's disease therapy., PMID:37249522
Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease., PMID:38096402
Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis., PMID:38321317
[Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti Integrins]., PMID:39176460
Gut-directed therapeutics in inflammatory bowel disease., PMID:40305008
Blood pressure lowering effects of a new long-acting inhibitor of phosphodiesterase 5 in patients with mild to moderate hypertension, PMID: 19398651
Physiologically relevant binding affinity quantification of monoclonal antibody PF-00547659 to mucosal addressin cell adhesion molecule for in vitro in vivo correlation, PMID: 27760281
Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA Study, PMID: 28961770
Anti-MAdCAM Antibody Increases ß7+ T Cells and CCR9 Gene Expression in the Peripheral Blood of Patients With Crohn's Disease, PMID: 28961803
Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study, PMID: 28982740
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial, PMID: 28527704
Normal intrathecal leukocyte cell number and composition do not decrease the incidence of post-lumbar puncture headache, PMID: 28778448
Molecular Profiling of Ulcerative Colitis Subjects from the TURANDOT Trial Reveals Novel Pharmacodynamic/Efficacy Biomarkers, PMID: 30901380
IBD: Phase II trial success for anti-MADCAM1 antibody, PMID: 28611481
Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): Insights into promising agents, PMID: 34449288
Towards therapeutic choices in ulcerative colitis, PMID: 28527707
Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases, PMID: 25110260
Rational and clinical development of the anti-MAdCAM monoclonal antibody for the treatment of IBD, PMID: 30696342
PF-00547659 for the treatment of Crohn's disease and ulcerative colitis, PMID: 29985060
Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease, PMID: 29767705
Targeting Endothelial Ligands: ICAM-1/alicaforsen, MAdCAM-1, PMID: 29757363
Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II, PMID: 33599720
Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study, PMID: 34427633
Anti-trafficking agents in the treatment of inflammatory bowel disease, PMID: 31567498
Anti-MADCAM therapy for ulcerative colitis, PMID: 31709847
Population Pharmacokinetics and Pharmacodynamics of Ontamalimab (SHP647), a Fully Human Monoclonal Antibody Against Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1), in Patients With Ulcerative Colitis or Crohn's Disease, PMID: 32119128
Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances, PMID: 31127023
For research use only. Not for human or drug use.
